Kezar Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Kezar Life Sciences Inc KZR.OQ reported a quarterly adjusted loss of $1.87​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.70. The mean expectation of six analysts for the quarter was for a loss of $2.39 per share. Wall Street expected results to range from $-2.78 to $-2.04 per share.

• Reported revenue was zero​; analysts expected zero.

• Kezar Life Sciences Inc's reported EPS for the quarter was a loss of $1.87​.

• The company reported a quarterly loss of $13.7 million.

• Kezar Life Sciences Inc shares had fallen by 14.8% this quarter and lost 42.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Kezar Life Sciences Inc is $12.50, about 68.8% above its last closing price of $3.90

This summary was machine generated from LSEG data August 13 at 08:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)